Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Talks Painful Reality Of Drug Development At NYAS Symposium

This article was originally published in The Pink Sheet Daily

Executive Summary

The 2013 Dr. Paul Janssen Awards honored UCSF’s David Julius for his work in pain, but both science and industry admits pain drug development is suffering due to the complexity and cost of the research.

You may also be interested in...

Huge Market Belies The Long And Difficult Road To Novel Pain Therapies

Since the introduction of the first triptan for aborting migraine in 1992, no truly new class of pain drug – other than off-label use of existing anticonvulsants and antidepressants for neuropathic pain – has reached the market. In fact, the vast majority of pain sufferers today are treated little differently than they would have been a century ago.

Lilly Halts Development of Glenmark’s TRVP-1 Receptor Antagonist

MUMBAI - Glenmark Pharmaceuticals suffered a major blow to its drug discovery plans as Eli Lilly, its research partner for the development of pain management compound GRC 6211 suspended further clinical development on the experimental drug

Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark

Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts